Calliditas Therapeutics IPO Presentation Deck

Strong product protection and product exclusivity for Nefecon Orphan designation Existing patents Patent strategy Soft barriers calliditas Granted orphan drug designation in the U.S. and E.U. Potential data protection and market exclusivity for 7 years (U.S.) and 10 years (E.U.) Calliditas has been granted patents covering Nefecon, its formulation and method of manufacturing The formulation patent runs until 2029 Strategic focus on the U.S. and Europe with extension into other geographical markets Significant formulation and manufacturing know-how Questionable relevance of bioequivalence studies Nefecon is the most advanced candidate in development June 2020 11

View entire presentation